Page 181 - Motor Disorders Third Edition

21. Sicot G, Gourdon G, Gomes-Pereira M. Myotonic dystro- NEUROGENETIC EVALUATION OF MOTOR DISORDERS / 163
phy, when simple repeats reveal complex pathogenic entities:
new findings and future challenges. Hum Mol Genet 2011;
20:R116–R123.
22. Kolb SJ, Sutton S, Schoenberg DR. RNA processing defects
associated with diseases of the motor neuron. Muscle Nerve
2010; 41:5–17.
23. Joyce PI, Fratta P, Fisher EM, et al. SOD1 and TDP-43 ani-
mal models of amyotrophic lateral sclerosis: recent advances
in understanding disease toward the development of clinical
treatments. Mamm Genome 2011; 22:420–448.
24. Coady TH, Lorson CL. SMN in spinal muscular atrophy and
snRNP biogenesis. Wiley Interdiscip Rev RNA 2011; 2:546–564.
25. Morrison LA. Dystrophinopathies. Handb Clin Neurol 2011;
101:11–39.
26. Fiskerstrand T, H’mida-Ben Brahim D, Johansson S, et al.
Mutations in ABHD12 cause the neurodegenerative disease
PHARC: An inborn error of endocannabinoid metabolism.
Am J Hum Genet 2010; 87:410–417.
27. Cagliani R, Fruguglietti ME, Berardinelli A, et al. New molecu-
lar findings in congenital myopathies due to selenoprotein N
gene mutations. J Neurol Sci 2011; 300:107–113.
28. Schoenmakers E, Agostini M, Mitchell C, et al. Mutations in
the selenocysteine insertion sequence-binding protein 2 gene
lead to a multisystem selenoprotein deficiency disorder in
humans. J Clin Invest 2010; 120:4220–4235.
29. Krzyzosiak WJ, Sobczak K, Wojciechowska M, et al. Triplet
repeat RNA structure and its role as pathogenic agent and
therapeutic target. Nucleic Acids Res 2012; 40:11–26.
30. Wright EM, Kerr B. RAS-MAPK pathway disorders: impor-
tant causes of congenital heart disease, feeding difficulties,
developmental delay and short stature. Arch Dis Child 2010;
95:724–730.
31. Lee SJ, Lim HS, Masliah E, et al. Protein aggregate spreading in
neurodegenerative diseases: Problems and perspectives. Neu-
rosci Res 2011; 70:339–348.
32. Blackstone C, O’Kane CJ, Reid E. Hereditary spastic paraple-
gias: membrane traffic and the motor pathway. Nat Rev Neuro-
sci 2011; 12:31-42.
33. Boespflug-Tanguy O, Labauge P, Fogli A, et al. Genes involved
in leukodystrophies: a glance at glial functions. Curr Neurol
Neurosci Rep 2008; 8:217–229.
34. Kimata Y, Kohno K. Endoplasmic reticulum stress-sensing
mechanisms in yeast and mammalian cells. Curr Opin Cell Biol
2011; 23:135–142.
35. Lax NZ, Turnbull DM, Reeve AK. Mitochondrial mutations:
newly discovered players in neuronal degeneration. Neurosci-
entist 2011; 17:645–658.
36. D’Aurelio M, Vives-Bauza C, Davidson MM, et al. Mitochon-
drial DNA background modifies the bioenergetics of NARP/
MILS ATP6 mutant cells. Hum Mol Genet 2010; 19:374–386.
37. D’Aurelio M, Vives-Bauza C, Davidson MM, et al. Mitochon-
drial DNA background modifies the bioenergetics of NARP/
MILS ATP6 mutant cells. Hum Mol Genet 2010; 19:374–386.
38. Broglio L, Tentorio M, Cotelli MS, et al. Limb-girdle muscu-
lar dystrophy-associated protein diseases. Neurologist 2010;
16:340–352.
39. Ozelius LJ, Bressman SB. Genetic and clinical features of pri-
mary torsion dystonia. Neurobiol Dis 2011; 42:127–135.
40. Drolet RE, Sanders JM, Kern JT. Leucine-rich repeat kinase 2
(LRRK2) cellular biology: a review of recent advances in iden-
tifying physiological substrates and cellular functions. J Neuro-
genet 2011; 25:140–151.
41. Matos CA, de Macedo-Ribeiro S, Carvalho AL. Polyglutamine
diseases: the special case of ataxin-3 and Machado-Joseph dis-
ease. Prog Neurobiol 2011; 95:26–48.
42. Piedrahita JA. The role of imprinted genes in fetal growth
abnormalities. Birth Defects Res A Clin Mol Teratol 2011;
91:682–692.
43. Delhanty JD. Inherited aneuploidy: germline mosaicism. Cyto-
genet Genome Res 2011; 133:136–140.
44. Zlotogora J. Multiple mutations responsible for frequent
genetic diseases in isolated populations. Eur J Hum Genet
2007; 15:272–278.
45. Bushby K. Diagnosis and management of the limb girdle mus-
cular dystrophies. Pract Neurol 2009; 9:314–323.
46. Wilmshurst JM, Ouvrier R. Hereditary peripheral neuropa-
thies of childhood: A brief overview for clinicians. Neuromus-
cul Disord 2011; 21:763–775.
47. Tazir M, Nouioua S, Magy L, et al. Phenotypic variabil-
ity in giant axonal neuropathy. Neuromuscul Disord 2009;
19:270–274.
48. Fabrizi GM, Cavallaro T, Angiari C, et al. Giant axonal and
neurofilament accumulation in Charcot-Marie-Tooth disease
type 2E. Neurology 2004; 62:1429–1431.
49. Quattrone A, Gambardella A, Bono F, et al. Autosomal reces-
sive hereditary moor and sensory neuropathy with focally
folded myelin sheaths: clinical, electrophysiologic, and genetic
aspects of a large family. Neurology 1996; 46:1318–1324.
50. Kessali M, Zemmouri R, Guilbot A, et al. Clinical, electro-
physiologic, neuropathologic, and genetic study of two large
Algerian families with an autosomal recessive demyelinat-
ing form of Charcot-Marie-Tooth disease. Neurology 1997;
48:867–873.
51. Muglia M, Zappia M, Timmerman V, et al. Clinical and genetic
study of a large Charcot-Marie-Tooth type 2A family from
southern Italy. Neurology 2001; 56:100–103.
52. Ippel EF, Wittebol-Post D, Jennikens FGI, et al. Genetic hetero-
geneity of hereditary motor and sensory neuropathy type VI.
Child Neurol 1995; 10:459–463.
53. Sparks SE, Escolar DM. Congenital muscular dystrophies.
Handb Clin Neurol 2011; 101:47–79.
54. Chang KH, Bonig H, Papayannopoulou T. Generation and
characterization of erythroid cells from human embryonic
stem cells and induced pluripotent stem cells; an overview.
Stem Cells Int 2011; Article ID 791604.
55. Valenzano KJ, Khanna R, Powe AC, Boyd et al. Identification
and characterization of pharmacological chaperones to cor-
rect enzyme deficiencies in lysosomal storage disorders. Assay
Drug Dev Technol 2011; 9:213–235.
56. Rowe SM, Clancy JP. Pharmaceuticals targeting nonsense
mutations in genetic diseases: progress in development. Bio-
Drugs 2009; 23:165–174.
57. Bowers WJ, Breakefield XO, Sena-Esteves M. Genetic therapy
for the nervous system. Hum Mol Genet 2011; 20:R28–R41.
58. Beck M. Therapy for lysosomal storage disorders. IUBMB Life
2010; 62:33–40.
59. Shadrach JL, Wagers AJ. Stem cells for skeletal muscle repair.
Philos Trans R Soc Lond B Biol Sci 2011; 366:2297–2306.
60. Gropman AL, Adams DR. Atypical patterns of inheritance.
Semin Pediatr Neurol 2007; 14:34–45.
61. Hammond SM, Wood MJ. Genetic therapies for RNA mis-
splicing diseases. Trends Genet 2011; 27:196–205.
62. Wilton SD, Fletcher S. RNA splicing manipulation: strategies
to modify gene expression for a variety of therapeutic out-
comes. Curr Gene Ther 2011; 11:259–275.